Nucleoside analogues toxicities related to mitochondrial dysfunction: Focus on HIV-infected children

Antiviral Therapy

Volumn 10, Issue SUPPL. 2, 2005, Pages

  Viganò, Alessandra ^a   Giacomet, Vania ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CARDIOMYOPATHY; CLINICAL TRIAL; CONFERENCE PAPER; FATTY LIVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIVER FAILURE; MITOCHONDRIAL TOXICITY; MYOPATHY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; CARDIOMYOPATHIES; CHILD; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MITOCHONDRIA; NUCLEOSIDES; POLYNEUROPATHIES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 24044455416     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (98)

1. De Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rexxa G & Pezzotti P for the Italian Register for HIV Infection in Children and the Italian National AIDS Registry. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Journal of the American Medical Association 2000; 184:190-197.
2. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonnaire X, Amiel C, Maurage CA, Robin S, Sablonniere B, Dhennain C & Mouton Y. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14:2723-2730.
3. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SM. Chronic hyperlactataemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
4. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Franciolo P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33:1931-1937.
5. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D & Gazzard BG. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 14:1341-1349.
6. John M & Mallal S. Hyperlactactaemia syndromes in people with HIV infection. Current Opinion in Infectious Diseases 2002; 15:23-29.
7. Konig H, Behr E, Lower J & Kurth R. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrobial Agents & Chemotherapy 1989; 33:2109-2114.
8. Chen C, Vasquez-Padua M & Cheng Y. Effect of anti human immunodefiency virus nucleoside analogues on mitochondrial DNA and its implication for delayed toxicity. Molecular Pharmacology 1991; 39:625-628.
9. Brinkman K, ter Hofstede JM, Burger DM, Smeitink JAM & Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
10. White AJ. Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections 2001; 77:158-173.
11. Mokrzycki M, Harris C, May H, Laut J & Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clinical Infectious Diseases 2000; 30:198-200.
12. Lonergan JL, Behling C, Pfander H, Hassanein TT & Mathews WC. Hyperlactataemia and hepatic abnormalities in ten human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clinical Infectious Diseases 2000; 31:162-166.
13. Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS & Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clinical Infectious Diseases 2001; 33:1911-1921.
14. Falco V, Rodriguez D, Ribera E, Martinez E, Mirò JM, Domingo P, Diazaraque R, Arribas JR, Gonzales-Garcia JJ, Montero F, Sanchez L & Pahissa A. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clinical Infectious Diseases 2002; 34:838-846.
15. Brinkman K. Management of hyperlactataemia: no need for routine lactate measurements. AIDS 2001; 15:795-797.
16. Mizock BA & Falk JL. Lactic acidosis in critical illness. Critical Care Medicine 1992; 20:80-93.
17. Miller KD, Cameron M, Wood LV, Dalakas MC & Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Annals of Internal Medicine 2000; 133:192-196.
18. Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH, Dimauro S & Boles RG. Mitochondrial DNA depletion, near-fatal metabolic acidosis and liver failure in an HIV-infected child treated with combination antiretroviral therapy. Journal of Pediatrics 2001; 138:748-751.
19. Rey C, Prieto S, Medina A, Perez C, Concha A & Menendez S. Fatal lactic acidosis during antiretroviral therapy. Pediatric Critical Care Medicine 2003; 4:485-487.
20. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, Bernuau J, Lucet JC & Trepo C. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. Journal of Internal Medicine 1994; 235:367-371.
21. Bleeker-Rovers CP, Kadir SW, van Leusen R & Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Netherlands Journal of Medicine 2000; 57:190-193.
22. Fortgang IS, Belitsos PC, Chaisson RE & Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. American Journal of Gastroenterology 1995; 90:1433-1436.
23. Hofstede HJM, de Marie S, Foudraine NA, Danner SA & Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. International Journal of STD & AIDS 2000; 11:611-616.
24. Noguera A, Fortuny C, Sanchez E, Arthuch R, Vilaseca MA, Munoz-Almagro C, Pou J & Jimenez R. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatric Infections Disease Journal 2003; 22:778-782.
25. Desai N, Mathur M & Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003; 17:1565-1567.
26. Lipshultz SE, Chanock S, Sanders SP, Colan SD & McIntosh K. Cardiac manifestations of human immunodeficiency infection in infants and children. American Journal of Cardiology 1989; 63:1489-1497.
27. Tovo PA, de Martino M, Gabiano C, Cappello N, D'Elia R & Loy A. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992; 339:1249-1253.
28. Luginbuhul LM, Orav EJ, McIntosh K & Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. Journal of the American Medical Association 1993; 269:2869-2875.
29. Turner BJ, Denison M, Eppes SC, Houchens R, Fanning T & Markson LE. Survival experience of 789 children with the acquired immunodeficiency syndrome. Pediatric Infectious Disease Journal 1993; 12:310-320.
30. Grenier MA, Karr SS, Rakusan TA & Martin GR. Cardiac-disease in children with HIV: relationship of cardiac disease to HIV symptomatology. Pediatric AIDS of HIV Infection 1994; 5:174-179.
31. Italian Register for HIV Infection in Children. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994; 343:191-195.
32. Lipshultz SE, Orav EJ, Sanders SP & Colan SD. Immunoglobulin and left ventricular struture and function in paediatric HIV infection. Circulation 1995; 92:2220-2225.
33. Lipshultz SE, Bancroft EA & Boller A-M. Cardiovascular manifestations of HIV infection in children. In The Science and Practice of Pediatric Cardiology. 1997 2nd edn. Edited by JT Bricker, A Garson Jr, DJ Fisher & SR Neish. Baltimore, MD: Williams-Wilkins.
34. 2 HIV Study Group. Postmortem cardiomegaly correlates with premortem measurements of left ventricular size in malnourished HIV-infected children. 3rd Conference on Retroviruses & Opportunistic Infections. 28 January-1 February 1996, Washington, DC, USA. Abstract 431.
35. Lindegren ML, Caldwell B & Oxtoby M. Paediatric HIV infection in the USA. In A Guide to Pratical Management, 1995; pp. 21-51. Edited by JYQ Mok & M-L Newell. New York: Cambridge University Press.
36. 2 Study. 3rd Conference on Retroviruses & Opportunistic Infections. 28 January-1 February 1996, Washington DC, USA. Abstract 415.
37. Lobato MN, Caldwell B, Ng P & Oxtoby MJ. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Journal of Pediatrics 1995; 126:710-715.
38. 2 study. 2nd National Conference on Human Retroviruses & Related Infections. 29 January-2 February 1995, Washington DC, USA. Abstract 193.
39. Lamperth T, Dalakas MC, Dagani F, Anderson J & Ferrari R. Abnormal skeletal and cardiac muscle mitocnondrial in vitro and in an animal model. Laboratory Investigations 1991; 6:742-751.
40. Gerschenson M, Erhart SW, Paik CY, Nagashima K, Skopels B, Harbaugh SW, Harbaugh JW, Quan W & Poirier MC. Fetal mitochondrial heart and skeletal muscle damage in Erytrocebus patas monkeys exposed in utero 3′-azido- 3′-deoxythymidine. AIDS Research & Human Retroviruses 2000; 16:635-644.
41. Lewis W, Grupp I, Grupp G, Hoit B, Morris R, Samarel AM, Bruggeman L & Klotman P. Cardiac dysfuction in the HIV-1 transgenic mouse treated with zidovudine. Laboratory Investigations 2000; 80:187-197.
42. Rerkpattanapipat P, Wongpraparut N, Jacobs LE & Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Archives of Internal Medicine 2000; 160:602-608.
43. Herskowitz A, Willoughby SB, Baughman KI, Schulman SP & Bartleit JD. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Annals of Internal Medicine 1992, 18:1260-1265.
44. Cardoso JS, Moura B, Mota-Miranda A, Goncalves FR & Lecour H. Zidovudine therapy and left ventricular function and mass in human immunodeficiency virus-infected patients. Cardiology 1997; 88:26-28.
45. Steinherz L, Broschstein JA & Robins J. Cardiac involvement in congenital acquired immunodeficiency syndrome. American Journal of Diseases of Children 1986; 140:1241-1244.
46. Joshi VV, Gadol C, Connor E, Oleske JM, Mendelson J & Marin-Garcia J. Dilated cardiomyopathy in children with acquired immunodeficiency syndrome: a pathologic study of five cases. Human Pathology 1988; 19:69-73.
47. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, McIntosh K & Colan SD. Cardiac structure and function in children with human immunodeficiency infection treated with zidovudine. New England Journal of Medicine 1992; 327:1260-1265.
48. Lipshultz SE, Kirk A, Easley MS, Orav EJ, Kaplan S, Starc TJ, Bricker T, Lai WW, Moodie DS, McIntosh K, Schluchter MD & Colan SD. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998; 97:1246-1256.
49. Lipshultz SE, Kirk A, Easley MS, Orav EJ, Kaplan S, Starc TJ, Bricker T, Lai WW, Moodie DS, McIntosh K, Schluchter MD & Colan SD. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. New England Journal of Medicine 2000; 343:759-766.
50. Domanski MJ, Sloas MM, Follmann DA, Scalise PP, Tucker EE, Egan D & Pizzo PA. Effect of zidovudine and didanosine on heart function in children infected with human immunodeficiency virus. Journal of Pediatrics 1995; 127:137-146.
51. Saulsbury FT. Resolution of organ-specific complications of immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clinical Infectious Diseases 2001; 32:464-468.
52. Cornblath DR & McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1998; 38:794-796.
53. Fuller GN, Jacobs JM & Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. Journal of Neurology, Neurosurgery & Psychiatry 1993; 56:372-381.
54. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP, Wills RJ, McAtee N, Fischl MA, Dubinsky R, McNeely MC, Mitauya H, Pluda JM, Lawley TJ, Luther M, Safai B, Collins JM, Myers CE & Broder S. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine. Lancet 1988; 1:76-82.
55. Merigan TC, Skowron G, Bozzette SA, Richman D, Uttamchandani R, Fischi M, Schooley R, Hirsch M, Soo W & Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Annals of Internal Medicine 1989; 110:189-194.
56. Fischi MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH & Nauss-Karol C. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Annals of Internal Medicine 1993; 118:762-769.
57. Package Insert Videx (didanosine). October 1991. New York: Bristol-Meyer-Squibb.
58. Rozeneweig M, McLaren C, Beltangady M, Ritter J, Canetta R, Schacter L, Kelley S, Nicaise C, Smaldone L & Dunkle L. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Reviews of Infectious Diseases 1990; 12:570-575.
59. Keilbaugh SA, Prusoff WH & Simpson VWV. The PC12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV dideoxynucleoside analogs. Biochemical Pharmacology 1991; 42:R5-R8.
60. Dalakas MC, Semino-Mora C & Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycitidine (ddC). Laboratory Investigations 2001; 81:1537-1544.
61. Simpson DM & Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995; 9:153-161.
62. Famularo G, Moretti S, Marcellini S, Trinchieri V, Tzantzoglou S, Santini G, Longo A & De Simone C. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral NRTI. AIDS 1997; 11:185-190.
63. Forloni G, Angeretti N & Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. Journal of Neuroscience Research 1994; 37:92-96.
64. Civitello LA. Neurologic complications of HIV infection in children. Pediatric Neurosurgery 1991; 17:104-112.
65. Pizzo PA, Butler K, Balis F, Brouwers E, Hawkins M, Eddy J, Einloth M, Falloon J, Husson R & Jarosinski P. Dideoxycitidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. Journal of Pediatrics 1990; 117:799-808.
66. Raphael SA, Price ML, Lischner HW, Griffin JW, Grover WD & Bagarsa O. Inflammatory demyelinating polyneuropathy in a child with symptomatic human immunodeficiency virus infection. Journal of Pediatrics 1991; 118:242-245.
67. Floeter MK, Civitell LA, Everett CR, Dambrosia J & Luciano CA. Peripheral neuropathy in children with HIV infection. Neurology 1997; 49:207-212.
68. Prufer de QC Araujo A, Nascimento OJM & Garcia OS. Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age. Pediatrics 2000; 106:E35.
69. Komiya Y. Axonal regeneration in bifurcating axons of dorsal root ganglion cells. Experimental Neurology 1981; 73:824-826.
70. Gamstorp I. Normal nerve conduction velocity of ulnar, median and peroneal nerves in infancy, childhood and adolescence. Acta Paediatrica 1963; 14(suppl 146):68-76.
71. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG & Saag MS. Management of metabolic complication associated with antiretroviral therapy for HIV-1 infection: recommendation of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes 2002; 31:257-275.
72. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M & Telenti A. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 2002; 31:50-55.
73. Health KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV & Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipia abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes 2002; 30:440-447.
74. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B & Viganò A. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001; 15:2415-2422.
75. Arpadi SM, Cuff PA, Horlick M, Wang J & Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. Journal of Acquired Immune Deficiency Syndromes 2001; 27:30-34.
76. Seidell JC, Bakker CJG & Van der Kooy K. Imaging techniques for measuring adipose tissue distribution. A comparison between computed tomography and 1.5 T magnetic resonance. American Journal of Clinical Nutrition 1990; 51:953-957.
77. Ellis KJ, Shypailo RJ, Pratt JA & Pond WG. Accuracy of dual-energy X-ray absorptiometry for body-composition measurements in children. American Journal of Clinical Nutrition 1994; 60:660-665.
78. He Q, Horlick M, Fedun B, Wang J, Pierson RN, Heshka S & Gallagher D. Trunk fat and blood pressure in children through puberty. Circulation 2002; 105:1093-1096.
79. Lohman TG, Roche F & Martorell R (Editors). Anthropometric standardization reference manual, 1988. Champaign, IL, USA: Human Kinetics Books.
80. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E & Levy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14:2123-2128.
81. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H & Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 2002; 21:405-410.
82. Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P & Brambilla P. Increased lipodystrophy with increased exposure to highly active antiretroviral therapy in HIV-infected children. Journal of Acquired Immune Deficiency Syndromes 2003; 32:482-489.
83. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
84. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC & Holmberg SD. Incidence of and risk factor for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 32:48-56.
85. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
86. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
87. Cossarizza A, Mussini C & Vigano A. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders? BioEssays 2001; 23:1070-1080.
88. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 2001; 15:413-414.
89. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29:117-121.
90. Shikuma CM, Hu N, Milne C, Yost F, Waslien C & Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
91. Hammond E, Nolan D, James I, Metcalf C & Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18:815-827.
92. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J & Cooper DA; Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
93. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC & Hernandez JE; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clinical Infectious Diseases 2004; 38:263-270.
94. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE & Ross LL. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
95. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C, Esposito R & Galli M. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antiviral Therapy 2003; 8:315-321.
96. Cossarizza A, Pinti M, Moretti L, Bricalli D, Bianchi R, Troiano L, Fernandez MG, Balli F, Brambilla P, Mussini C & Vigano A. Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. Journal of Infectious Diseases 2002; 185:299-305.
97. Ogedegbe AE, Thomas DL & Diehi AM. Hyperlactatemia syndromes associated with HIV therapy. Lancet Infectious Diseases 2003; 3:329-337.
98. Chinnery PF & Bindoff LA; European neuromuscular center. 116th ENMC international workshop: the treatment of mitochondrial disorders, 14th-16th March 2003, Naarden, The Netherlands. Neuromuscular Disorders 2003; 13:757-764.